Previous 10 | Next 10 |
WARREN, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...
2024-04-22 16:53:54 ET Gainers: Oportun Financial ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...
2024-04-17 08:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady...
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...
2024-04-11 14:48:40 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...
2024-04-11 12:38:15 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...
2024-04-09 01:25:13 ET Summary Aquestive Therapeutics has achieved positive Phase III data for their Anaphylm epinephrine sublingual film, showing comparable efficacy to auto-injectors. The company is moving forward with plans to file a New Drug Application (NDA) and has several u...
2024-04-03 17:38:46 ET More on Aquestive Therapeutics Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1 Aquestive Therapeutics slumps 13%, prices $75M offering Aquestive Therapeutics reports mixed Q4 results; initiates FY24 outlook ...
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...
WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery t...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pH Remains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024 Continues to anticipate filin...
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...